Abbott announced its intention to separate its global Nutrition business into an independent publicly traded company through a tax-free distribution to existing shareholders, with completion expected by the end of 2027.
The business generates approximately $8.5 billion in annual sales, employs about 16,000 people, and operates 14 manufacturing sites. Its brands include Similac, Ensure, PediaSure, Pedialyte, and Glucerna.
Following the separation, Abbott expects to retain approximately $42 billion in annual sales, concentrated in medical devices, diagnostics, biowearables, and established pharmaceuticals.
The company also reported third-quarter revenue of $13.01 billion and lowered its 2026 comparable sales-growth outlook to approximately 6%, while narrowing adjusted EPS guidance to $5.50–$5.55. Abbott MediaRoom
Primary sources: Abbott — Nutrition separation announcement, October 21 · Abbott — Q3 financial results
Why it matters strategically
The announced transaction involves two different strategic objectives.
First, portfolio optimization.
Abbott intends to concentrate its remaining capital and management resources on businesses with stronger growth prospects.
These include cardiovascular devices, diabetes monitoring, diagnostics, and other medical technologies.
Second, independent capital allocation.
The Nutrition business would gain its own balance sheet, management team, financing strategy, and investment priorities.
However, a corporate separation does not automatically increase the combined economic value of the underlying businesses.
The transaction creates value only if the benefits of specialization, improved capital allocation, and potentially different market valuations exceed separation costs and any loss of operational synergies.
